Becky McCall on Muck Rack

Becky McCall

Verified
South East District
As seen in: Daily Mail, Nature, WebMD, Flipboard, Medscape, Medscape Duestch, Medscape France, Medscape Noticias Médicas, Medscape PT, MedicineNet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Becky

Contact Becky, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

High Type 2 Biomarkers Identify Patients Most Likely to Benefit From Dupilumab

|
By Becky McCall Verified
| Medscape Verified
Patients with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) experienced significantly greater improvements in lung function, asthma control, smell function, and nasal polyp burden with dupilumab than with omalizumab, with the largest benefits seen in those with highly elevated biomarkers of type 2 inflammation.
Open in Who Shared Issue with article?

Intramuscular Adrenaline Failed to Reverse Hypotension in Human Histamine Model Mimicking Anaphylaxis

|
By Becky McCall Verified
| Medscape Verified
Standard doses of intramuscular adrenaline failed to reverse severe hypotension in most participants exposed to a controlled histamine challenge designed to mimic anaphylactic shock, according to results of the first randomized placebo-controlled study of its kind. The findings raise questions about whether current emergency intramuscular adrenaline dosing strategies are sufficient to reverse the most severe cardiovascular manifestations of anaphylaxis.
Open in Who Shared Issue with article?

One Third of Infants Referred for Peanut Immunotherapy Found Not to Be Allergic

|
By Becky McCall Verified
| Medscape Verified
More than one third of infants referred for peanut oral immunotherapy (OIT) were found not to be allergic when formally challenged, according to findings from Australia’s national ADAPT Peanut OIT Program.
Open in Who Shared Issue with article?
See all 647 licensed articles (653 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified